Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

CEO Albert Bourla sits down with Yahoo Finance Executive Editor Brian Sozzi to talk about when consumers can expect to see ...

In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula ...

Technology is no longer a vertical; it’s the backbone of national security and economic strength,” Michael Kratsios, director ...

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

Johnson & Johnson's planned $3 billion acquisition of Halda Therapeutics is one of the largest deals for a CT-based biotech ...

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

Merck KGaA has teamed up with Flagship Pioneering's Valo Health on an ambitious project to apply AI to the discovery of novel ...

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation ...

As the biopharma world predominantly invests in late-stage assets, Eli Lilly is prioritizing early science with the opening ...

The vote was a crucial next step for the fragile cease-fire and efforts to outline Gaza’s future following two years of war ...